Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review

Cancer Communications, Journal Year: 2021, Volume and Issue: 41(12), P. 1257 - 1274

Published: July 31, 2021

Abstract Pancreatic cancer is a highly malignant digestive system tumor with poor prognosis. Most pancreatic patients are diagnosed at an advanced stage or even metastasis due to its aggressive characteristics and lack of typical early symptoms. Thus, diagnosis crucial for improving Currently, screening often applied in high‐risk individuals achieve the cancer. Fully understanding risk factors pathogenesis could help us identify population timely treatment Notably, accumulating studies have been undertaken improve detection rate different imaging methods diagnostic accuracy endoscopic ultrasound‐guided fine‐needle aspiration (EUS‐FNA) which golden standard diagnosis. In addition, there currently no biomarkers sufficient sensitivity specificity be clinic. As only serum biomarker approved by United States Food Drug Administration, carbohydrate antigen 19‐9 (CA19‐9) not recommended used because limited specificity. Recently, increasing numbers focused on discovering novel exploring their combination CA19‐9 Besides, application liquid biopsy involving circulating cells (CTCs), DNA (ctDNA), microRNAs (miRNAs), exosomes blood urine, saliva drawing more attention. Furthermore, many innovative technologies such as artificial intelligence, computer‐aided system, metabolomics technology, ion mobility spectrometry (IMS) associated technologies, nanomaterials tested shown promising prospects. Hence, this review aims summarize recent progress development methods, including imaging, pathological examination, serological biopsy, well other potential strategies

Language: Английский

---

A one-pot isothermal Cas12-based assay for the sensitive detection of microRNAs

Nature Biomedical Engineering, Journal Year: 2023, Volume and Issue: 7(12), P. 1583 - 1601

Published: April 27, 2023

Language: Английский

---

An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study

Gastroenterology, Journal Year: 2022, Volume and Issue: 163(5), P. 1252 - 1266.e2

Published: July 16, 2022

Language: Английский

---

Overview and countermeasures of cancer burden in China

Science China Life Sciences, Journal Year: 2023, Volume and Issue: 66(11), P. 2515 - 2526

Published: April 13, 2023

Language: Английский

---

Artificial intelligence in pancreatic cancer

Theranostics, Journal Year: 2022, Volume and Issue: 12(16), P. 6931 - 6954

Published: Jan. 1, 2022

Pancreatic cancer is the deadliest disease, with a five-year overall survival rate of just 11%.The pancreatic patients diagnosed early screening have median nearly ten years, compared 1.5 years for those not screening.Therefore, diagnosis and treatment are particularly critical.However, as rare general cost high, accuracy existing tumor markers enough, efficacy methods exact.In terms diagnosis, artificial intelligence technology can quickly locate high-risk groups through medical images, pathological examination, biomarkers, other aspects, then lesions early.At same time, algorithm also be used to predict recurrence risk, metastasis, therapy response which could affect prognosis.In addition, widely in health records, estimating imaging parameters, developing computer-aided systems, etc. Advances AI applications will require concerted effort among clinicians, basic scientists, statisticians, engineers.Although it has some limitations, play an essential role overcoming foreseeable future due its mighty computing power.

Language: Английский

---

Liquid Biopsies, Novel Approaches and Future Directions

Cancers, Journal Year: 2023, Volume and Issue: 15(5), P. 1579 - 1579

Published: March 3, 2023

Cancer is among the leading causes of death worldwide. Early diagnosis and prognosis are vital to improve patients’ outcomes. The gold standard tumor characterization tissue biopsy. Amongst constraints biopsy collection sampling frequency incomplete representation entire bulk. Liquid approaches, including analysis circulating cells (CTCs), DNA (ctDNA), miRNAs, tumor-derived extracellular vesicles (EVs), as well certain protein signatures that released in circulation from primary tumors their metastatic sites, present a promising more potent candidate for patient follow up monitoring. minimally invasive nature liquid biopsies, allowing frequent collection, can be used monitoring therapy response real time, development novel approaches therapeutic management cancer patients. In this review we will describe recent advances field markers focusing on advantages disadvantages.

Language: Английский

---

Graphene Sensor Arrays for Rapid and Accurate Detection of Pancreatic Cancer Exosomes in Patients’ Blood Plasma Samples

ACS Nano, Journal Year: 2023, Volume and Issue: 17(15), P. 14619 - 14631

Published: July 20, 2023

Biosensors based on graphene field effect transistors (GFETs) have the potential to enable development of point-of-care diagnostic tools for early stage disease detection. However, issues with reproducibility and manufacturing yields sensors, but also Debye screening unwanted detection nonspecific species, prevented wider clinical use technology. Here, we demonstrate that our wafer-scalable GFETs array platform enables meaningful results. As a case study high relevance, an accurate robust portable GFET biosensor pancreatic ductal adenocarcinoma (PDAC) in patients' plasma through specific exosomes (GPC-1 expression) within 45 min. In order facilitate reproducible blood plasma, optimized analytical performance biosensors via application internal control channel test protocol. Based samples from 18 PDAC patients 8 healthy controls, arrays could accurately discriminate between two groups while being able detect cancer stages including 1 2. Furthermore, confirmed higher expression GPC-1 found concentration was average more than magnitude samples. We these characteristics cancerous are responsible increase number target surface graphene, leading improved signal response biosensors. This holds great promise tool rapid diagnosis cancer.

Language: Английский

---

Glycan-specific molecularly imprinted polymers towards cancer diagnostics: merits, applications, and future perspectives

Chemical Society Reviews, Journal Year: 2024, Volume and Issue: 53(4), P. 1870 - 1891

Published: Jan. 1, 2024

This review surveys glycans as biomarkers and challenges in using glycan-binding receptors for cancer diagnosis. We highlight merits, applications, future directions of molecularly imprinted polymers effective receptors.

Language: Английский

---

miRNAs in pancreatic cancer progression and metastasis

Clinical & Experimental Metastasis, Journal Year: 2024, Volume and Issue: 41(3), P. 163 - 186

Published: Jan. 19, 2024

Abstract Small non-coding RNA or microRNA (miRNA) are critical regulators of eukaryotic cells. Dysregulation miRNA expression and function has been linked to a variety diseases including cancer. They play complex role in cancers, having both tumour suppressor promoter properties. In addition, single can be involved regulating several mRNAs many miRNAs regulate mRNA, therefore assessing these roles is essential better understanding cancer initiation development. Pancreatic leading cause death worldwide, part due the lack diagnostic tools limited treatment options. The most common form pancreatic cancer, ductal adenocarcinoma (PDAC), characterised by major genetic mutations that drive progression. regulation interaction with driving suggests strong link between two. Understanding this PDAC progression may give rise novel treatments tools. This review summarises PDAC, downstream signalling pathways they in, how being used studied as therapeutic targets well prognostic/diagnostic improve clinical outcome PDAC.

Language: Английский

---

Global, regional, and national burdens of early onset pancreatic cancer in adolescents and adults aged 15–49 years from 1990 to 2019 based on the Global Burden of Disease Study 2019: a cross-sectional study

International Journal of Surgery, Journal Year: 2024, Volume and Issue: 110(4), P. 1929 - 1940

Published: Jan. 11, 2024

Background: Early-onset pancreatic cancer (EOPC) in younger populations (age ≤50 years) is likely to be a more aggressive phenotype characterized by poor differentiation. The emerging analysis of the global burden EOPC limited and outdated. Aim: To systematically investigate trend based on populations. Methods: In this systematic Global Burden Diseases, Injuries, Risk Factors Study (GBD) 2019, authors present number cases, age-standardized rates (ASRs) per 100 000 population, risk factors for 204 countries territories. average annual percentage changes (AAPCs) incidence, mortality, disability-adjusted life-years (DALYs) were calculated using joinpoint regression analysis. Results: According GBD 2019 estimates, there 36 852 new cases 32 004 related deaths. East Asia had highest with 11 401 incidences 10 149 ASRs 0.94 individuals incidence 0.81 mortality. From 1990 increased 46.9%, mortality 44.6%, DALYs 41.9% globally. analysis, (AAPC, 1.26), 1.24), 1.25) showed an increasing pattern. Africa, America, exhibited continuous upward trend, while Europe was fluctuating. Asian males fastest growth 2.15) 2.13), whereas Americas experienced slowest increase 0.72) deaths 0.67). A certain proportion attributable known factors: tobacco smoking (13.3%), high BMI, 5.6%, fasting plasma glucose 3.2%. Integrating socio-demographic index (SDI), initially rising SDI, reaching peak central (1.5 <ASRs <2.0 000), decreased further SDI 2019. Conclusions: findings offer valuable insights into distribution magnitude burden. at rapid pace worldwide, particularly Asia, notably eastern Europe. This highlights need additional preventive control efforts targeting high-risk

Language: Английский

---